Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF 89 3-Year EBITDA Growth Rate is 17.00% as of Jun. 2026, which is 11% above its 10-year median of 15.30. GuruFocus rates HKMPF with a GF Score™ of 89/100 and a GF Value™ of $27.63 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 64.03% on this metric.
During the past 12 months, Hikma Pharmaceuticals's average EBITDA Per Share Growth Rate was 22.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 4.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hikma Pharmaceuticals was 43.40% per year. The lowest was -4.20% per year. And the median was 15.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hikma Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
HKMPF vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.00% mean?
Hikma Pharmaceuticals (HKMPF) has a 3-Year EBITDA Growth Rate of 17.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hikma Pharmaceuticals and its competitors. This is 11% above median its historical median of 15.30. According to the industry distribution chart, Hikma Pharmaceuticals ranks #291 out of 809 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is Hikma Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Hikma Pharmaceuticals' current 3-Year EBITDA Growth Rate of 17.00% is 11% above median its 10-year median of 15.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Hikma Pharmaceuticals' value of 17.00% is 91% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #291 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #291 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Hikma Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Hikma Pharmaceuticals' value of 17.00% is 91% above this benchmark. While the company's 10-year median is 15.30 vs. the industry median of 8.90, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current 3-Year EBITDA Growth Rate of 17.00% is 91% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current 3-Year EBITDA Growth Rate is 17.00%, which is 11% above median its own 10-year median of 15.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.63, compared to a current price of $22.19 — trading 19.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.00%, which is 11% above median its 10-year median of 15.30 and 91% above the Drug Manufacturers industry median of 8.90. Hikma Pharmaceuticals' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current 3-Year EBITDA Growth Rate is 17.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $22.19 is trading 19.7% below its estimated GF Value™ of $27.63.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
3-Year EBITDA Growth Rate: 17.00% (11% above median its 10-year median of 15.30)
GF Value™: $27.63 vs. price of $22.19 (19.7% below fair value)
Industry Position: 91% above the Drug Manufacturers median (#291 of 809)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
89GF Score
Get the complete analysis for HKMPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
